Mayne Pharma Group Limited
MAYNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $195,041 | $213,054 | $200,473 | $187,926 |
| % Growth | -8.5% | 6.3% | 6.7% | – |
| Cost of Goods Sold | $78,626 | $82,195 | $87,481 | $113,606 |
| Gross Profit | $116,415 | $130,859 | $112,992 | $74,320 |
| % Margin | 59.7% | 61.4% | 56.4% | 39.5% |
| R&D Expenses | $8,614 | $10,858 | $10,648 | $10,244 |
| G&A Expenses | $54,189 | $60,357 | $43,910 | $11,617 |
| SG&A Expenses | $125,053 | $126,342 | $109,602 | $76,622 |
| Sales & Mktg Exp. | $70,864 | $65,985 | $65,692 | $65,005 |
| Other Operating Expenses | $0 | $0 | $0 | $26,289 |
| Operating Expenses | $133,667 | $137,200 | $120,250 | $113,155 |
| Operating Income | -$17,252 | -$6,341 | -$100,228 | -$131,805 |
| % Margin | -8.8% | -3% | -50% | -70.1% |
| Other Income/Exp. Net | -$51,325 | -$8,378 | -$14,994 | $56,940 |
| Pre-Tax Income | -$68,577 | -$14,719 | -$115,222 | -$74,865 |
| Tax Expense | $1,524 | $5,251 | -$17,152 | -$4,316 |
| Net Income | -$68,291 | -$25,545 | -$103,681 | -$70,552 |
| % Margin | -35% | -12% | -51.7% | -37.5% |
| EPS | -0.89 | -0.25 | -1.18 | -0.87 |
| % Growth | -256% | 78.8% | -35.6% | – |
| EPS Diluted | -0.89 | -0.25 | -1.24 | -0.87 |
| Weighted Avg Shares Out | 76,985 | 101,166 | 83,249 | 81,246 |
| Weighted Avg Shares Out Dil | 79,191 | 79,087 | 78,885 | 81,246 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $214 | $6,004 | $4,064 |
| Interest Expense | $35,102 | $0 | $4,806 | $2,299 |
| Depreciation & Amortization | $34,234 | $29,874 | $29,969 | $38,490 |
| EBITDA | $17,573 | $24,505 | $23,367 | -$110,494 |
| % Margin | 9% | 11.5% | 11.7% | -58.8% |